昊帆生物 (301393.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

30.9x

Market Cap

CNY 6.62B

MomentumView details →

1D Return

−6.28%

YTD Return

+9.94%

RSI (14)

40.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

30.9x

Market Cap

CNY 6.62B

RSI (14)

40.0

MomentumView details →

1D Return

−6.28%

YTD Return

+9.94%

ProfitabilityView details →

Gross Margin

34.16%

Net Margin

17.73%

EBITDA Margin

28.28%

ROE (TTM)

4.74%

ROA (TTM)

4.03%

Asset Turnover

0.23x

GrowthView details →

Revenue YoY

+28.86%

EPS YoY

−18.66%

FCF YoY

—

Revenue CAGR 3Y

+10.41%

EPS CAGR 3Y

−12.56%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.04x

Current Ratio

5.41x

Quick Ratio

4.90x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

638.98M

Net Income (TTM)

113.30M

Op. CF (TTM)

139.81M

Latest newsMore news →

Haofan Biotech announced its first-half 2026 results: revenue of 379 million yuan, up 40.30% year-on-year; net profit attributable to shareholders of 70.7463 million yuan, down 6.77% year-on-year.12d ago

Hangzhou First, a controlled subsidiary of Haofan Biotech, was prosecuted by the procuratorate for environmental pollution crimes.37d ago

Similar companies

志特新材300986.SZ 科力尔002892.SZ 安靠智电300617.SZ 贵州轮胎000589.SZ 德展健康000813.SZ 科泰电源300153.SZ

Latest newsMore news →

Haofan Biotech announced its first-half 2026 results: revenue of 379 million yuan, up 40.30% year-on-year; net profit attributable to shareholders of 70.7463 million yuan, down 6.77% year-on-year.12d ago Hangzhou First, a controlled subsidiary of Haofan Biotech, was prosecuted by the procuratorate for environmental pollution crimes.37d ago